769 related articles for article (PubMed ID: 15155147)
1. Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection.
Stout JE
Expert Opin Drug Saf; 2004 May; 3(3):187-98. PubMed ID: 15155147
[TBL] [Abstract][Full Text] [Related]
2. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis.
Gao XF; Wang L; Liu GJ; Wen J; Sun X; Xie Y; Li YP
Int J Tuberc Lung Dis; 2006 Oct; 10(10):1080-90. PubMed ID: 17044199
[TBL] [Abstract][Full Text] [Related]
3. Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected by the human immunodeficiency virus?
Tortajada C; Martínez-Lacasa J; Sánchez F; Jiménez-Fuentes A; De Souza ML; García JF; Martínez JA; Caylà JA;
Int J Tuberc Lung Dis; 2005 Mar; 9(3):276-81. PubMed ID: 15786890
[TBL] [Abstract][Full Text] [Related]
4. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
Nolan CM; Goldberg SV
Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics.
Lee AM; Mennone JZ; Jones RC; Paul WS
Int J Tuberc Lung Dis; 2002 Nov; 6(11):995-1000. PubMed ID: 12475146
[TBL] [Abstract][Full Text] [Related]
6. Two-month regimen of isoniazid, rifampin and pirazinamid for latent tuberculosis infection.
Duarte R; Carvalho A; Correia A
Public Health; 2012 Sep; 126(9):760-2. PubMed ID: 22633080
[No Abstract] [Full Text] [Related]
7. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment.
van Hest R; Baars H; Kik S; van Gerven P; Trompenaars MC; Kalisvaart N; Keizer S; Borgdorff M; Mensen M; Cobelens F
Clin Infect Dis; 2004 Aug; 39(4):488-96. PubMed ID: 15356811
[TBL] [Abstract][Full Text] [Related]
8. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity.
McNeill L; Allen M; Estrada C; Cook P
Chest; 2003 Jan; 123(1):102-6. PubMed ID: 12527609
[TBL] [Abstract][Full Text] [Related]
9. Initial experience on rifampin and pyrazinamide vs isoniazid in the treatment of latent tuberculosis infection among patients with silicosis in Hong Kong.
Leung CC; Law WS; Chang KC; Tam CM; Yew WW; Chan CK; Wong MY
Chest; 2003 Dec; 124(6):2112-8. PubMed ID: 14665488
[TBL] [Abstract][Full Text] [Related]
10. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study.
Page KR; Sifakis F; Montes de Oca R; Cronin WA; Doherty MC; Federline L; Bur S; Walsh T; Karney W; Milman J; Baruch N; Adelakun A; Dorman SE
Arch Intern Med; 2006 Sep; 166(17):1863-70. PubMed ID: 17000943
[TBL] [Abstract][Full Text] [Related]
11. Treatment of latent tuberculosis infection: renewed opportunity for tuberculosis control.
Cohn DL
Clin Infect Dis; 2000 Jul; 31(1):120-4. PubMed ID: 10913407
[TBL] [Abstract][Full Text] [Related]
12. Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures.
Tam CM; Chan SL; Kam KM; Goodall RL; Mitchison DA
Int J Tuberc Lung Dis; 2002 Jan; 6(1):3-10. PubMed ID: 11931398
[TBL] [Abstract][Full Text] [Related]
13. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial.
Jasmer RM; Snyder DC; Saukkonen JJ; Hopewell PC; Bernardo J; King MD; Kawamura LM; Daley CL;
Clin Infect Dis; 2004 Feb; 38(3):363-9. PubMed ID: 14727206
[TBL] [Abstract][Full Text] [Related]
14. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group.
Gordin F; Chaisson RE; Matts JP; Miller C; de Lourdes Garcia M; Hafner R; Valdespino JL; Coberly J; Schechter M; Klukowicz AJ; Barry MA; O'Brien RJ
JAMA; 2000 Mar; 283(11):1445-50. PubMed ID: 10732934
[TBL] [Abstract][Full Text] [Related]
15. Results of a 12-month regimen for drug-resistant pulmonary tuberculosis.
Pérez-Guzmán C; Vargas MH; Martínez-Rossier LA; Torres-Cruz A; Villarreal-Velarde H
Int J Tuberc Lung Dis; 2002 Dec; 6(12):1102-9. PubMed ID: 12546119
[TBL] [Abstract][Full Text] [Related]
16. [Procedure in case of suspected mycobacterial infection of lymph nodes of the neck. 2. Therapy].
Göpel B; Götte K
Laryngorhinootologie; 2005 Aug; 84(8):610-9; quiz 621-2. PubMed ID: 16080064
[TBL] [Abstract][Full Text] [Related]
17. [Stevens-Johnson syndrome and toxic epidermal necrolysis after intake of rifampicin-isoniazid: report of 8 cases in HIV-infected patients in Togo].
Pitche P; Mouzou T; Padonou C; Tchangai-Walla K
Med Trop (Mars); 2005 Sep; 65(4):359-62. PubMed ID: 16548490
[TBL] [Abstract][Full Text] [Related]
18. [Fulminant hepatitis in the course of antitubercular treatment (apropos of 2 cases)].
Mbaye PS; Talarmin F; Sane M; Eladari D; Klotz F
Dakar Med; 1995; 40(2):129-31. PubMed ID: 9827070
[TBL] [Abstract][Full Text] [Related]
19. [Fulminant hepatitis during the therapy for tuberculous meningitis].
Garavelli PL
Recenti Prog Med; 1996 Dec; 87(12):597. PubMed ID: 9102699
[No Abstract] [Full Text] [Related]
20. Multiple small bowel perforations in a patient on treatment of tuberculosis.
Scriven JM; Berry D
J R Coll Surg Edinb; 1996 Oct; 41(5):353. PubMed ID: 8908966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
